The EVICEL® Gastrointestinal Study

PHASE2CompletedINTERVENTIONAL
Enrollment

214

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

January 31, 2014

Study Completion Date

September 30, 2014

Conditions
Gastrointestinal Diseases
Interventions
BIOLOGICAL

EVICEL Fibrin Sealant

Intraoperative

Trial Locations (22)

2305

Clinical Investigation Site #19, New Lambton

3600

Clinical Investigation Site #17, Genk

6010

Clinical Investigation Site #18, South Adelaide

9000

Clinical Investigation Site #16, Ghent

29605

Clinical Investigation Site #23, Greenville

30912

Clinical Investigation Site #5, Augusta

32099

Clinical Investigation Site #2, Jacksonville

70121

Clinical Investigation Site #4, New Orleans

77030

Clinical Investigation Site #3, Houston

Clinical Investigation Site #6, Houston

92868

Clinical Investigation Site #1, Irvine

97239

Clinical Investigation Site #8, Portland

V6Z 1Y6

Clinical Investigation Site #10, Vancouver

M5G 1X5

Clinical Investigation Site #9, Toronto

0622

Clinical Investigation Site #20, Auckland

138-736

Clinical Investigation Site #22, Seoul

Unknown

Clinical Investigation Site #21, Seoul

EH42XU

Clinical Investigation Site #15, Edinburgh

LE15WW

Clinical Investigation Site #11, Leicester

NG72UH

Clinical Investigation Site #12, Nottingham

PL68DH

Clinical Investigation Site #13, Plymouth

S57AU

Clinical Investigation Site #14, Sheffield

All Listed Sponsors
lead

Ethicon, Inc.

INDUSTRY

NCT01589822 - The EVICEL® Gastrointestinal Study | Biotech Hunter | Biotech Hunter